Cue Biopharma Beats Earnings Expectations, Outperforming Market with a ‘Buy’ Rating

Cue Biopharma Inc. (CUE) exceeded earnings expectations in the second quarter of 2024, reporting a smaller-than-expected loss and exceeding revenue estimates. The company’s strong performance and positive earnings outlook have earned it a Zacks Rank #2 (Buy), indicating potential for outperformance in the near future. This comes despite the stock’s decline earlier this year. Meanwhile, the Medical – Biomedical and Genetics industry remains strong, suggesting continued positive momentum for Cue Biopharma.

Acreage Holdings Reports Mixed Q2 2024 Earnings: Revenue Dip Despite Strategic Expansions

Acreage Holdings, a leading cannabis operator, reported a mixed financial performance in Q2 2024. While the company expanded its market reach, notably with the entry into Ohio’s recreational cannabis market, revenue declined due to liquidity constraints. However, Acreage is optimistic about future growth, driven by recapitalization, new product launches, and the integration with Canopy USA.

US Stocks Surge on Strong Earnings, Cisco Leads the Charge

The US stock market closed higher on Thursday, with the Dow Jones index gaining over 350 points, fueled by positive earnings reports from major companies. Cisco Systems, Inc. (CSCO) led the gains after exceeding revenue and earnings expectations for its fiscal fourth quarter. Other notable performers included AST SpaceMobile, Gambling.com, Perpetua Resources, Lumentum Holdings, and TeraWulf, all reporting strong financial results.

Scroll to Top